Snapshot from Apr 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / ADARx Pharmaceuticals
Entity

ADARx Pharmaceuticals

Tracked across 1 events · 7 articles · First seen Feb 20, 2026 · Last active Feb 27, 2026

Sentiment
70
Attention
4
Events
1
Relationships
1
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 70
Tech
ADARx Pharmaceuticals Presents Positive Onvuzosiran Data
ADARx Pharmaceuticals announced positive Phase 1/2 clinical data for its investigational siRNA therapeutic candidate, onvuzosiran, for hereditary angioedema (HAE). This positive data supports the ongoing Phase 3 clinical trial and enhances the company's profile in RNA therapeutics.
Feb 20, 2026 · 7 articles
Relationships (1)
Donald Fong Chief Medical Officer ↔ ADARx Pharmaceuticals Donald Fong is the Chief Medical Officer of ADARx Pharmaceuticals.
NEWSDESK
Track ADARx Pharmaceuticals live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.